Analytical method development is a critical component of biologics development, enabling comprehensive characterization, quality evaluation, and regulatory support throughout the product lifecycle. For antibody therapeutics and antibody-based conjugates (AOCs), robust analytical strategies are essential to assess molecular identity, purity, structural integrity, biological activity, and critical quality attributes (CQAs). Protheragen provides comprehensive analytical method development services for antibodies, fusion proteins, and complex biologics, supporting programs from early-stage development through IND submission and further clinical development.
Overview of Antibody & AOC Analytical Method Development
Analytical method development is a fundamental part of Chemistry, Manufacturing, and Controls (CMC) activities for antibody and antibody-based therapeutics. Due to the structural complexity of biologics, analytical methods are required to characterize multiple quality attributes that may influence product safety, efficacy, stability, and manufacturability.
For monoclonal antibodies and antibody-related molecules, analytical strategies typically include assessment of molecular identity, purity, aggregation, charge heterogeneity, glycosylation patterns, post-translational modifications, residual impurities, and biological functions. A combination of orthogonal analytical techniques is often applied to achieve comprehensive molecular characterization and support product understanding.
During biologics development, analytical methods are continuously optimized and refined to support different development stages, including cell line development, upstream and downstream process optimization, formulation screening, stability studies, and regulatory submissions. Well-established analytical methods provide essential data for defining CQAs, evaluating process changes, demonstrating comparability, and preparing IND/BLA CMC documentation. For antibody-drug conjugates (AOCs), analytical development requires additional characterization strategies to evaluate conjugation-related attributes, molecular integrity, payload-related properties, and functional performance, ensuring consistent product quality throughout development and manufacturing.
Fig.1 Key critical quality attributes (CQAs) for monoclonal antibody characterization. (Aithal, R, et al., 2026)
Our Services
Protheragen provides analytical method development and characterization services covering product quality attributes, molecular structure, biological activity, and process-related impurities.
Purity and Product-Related Impurity Analysis
Evaluation of product purity, molecular variants, and aggregation profiles using orthogonal analytical techniques.
Analytical Platforms:
Size Exclusion Chromatography (SEC)
Reduced / Non-reduced CE-SDS
Isoelectric Focusing (icIEF)
Cation Exchange Chromatography (CEX)
Applications:
Aggregation analysis
Fragment detection
Charge variant profiling
Purity assessment
Identity and Molecular Characterization
Comprehensive structural characterization to confirm molecular identity and consistency.
Analytical Scope:
Peptide mapping and CDR characteristic peptide identification
Isoelectric point (pI) determination
Molecular weight analysis
Amino acid sequence coverage
N-terminal and C-terminal sequence confirmation
Disulfide bond mapping
Physical and Chemical Property Testing
Evaluation of essential physicochemical properties for biologics quality assessment.
Testing Parameters:
Appearance
Color and clarity
Visible particles
Subvisible particles
pH
Osmolality
Process-Related Impurity and Residual Analysis
Sensitive detection and quantification of process-related impurities to support quality evaluation.
Testing Items:
Host Cell Protein (HCP)
Host Cell DNA (Residual DNA)
Protein A Residue
Residual Surfactants
Free sulfhydryl groups
Product titer determination
Biological Activity Characterization
Evaluation of functional activity and mechanism-related biological properties.
Functional Assays:
Binding activity assays
Antibody-dependent cellular cytotoxicity (ADCC)
Complement-dependent cytotoxicity (CDC)
Post-Translational Modification (PTM) Analysis
Comprehensive characterization of molecular modifications affecting product quality, stability, and biological function.
PTM Analysis Includes:
Oxidation
Deamidation
N-terminal pyroglutamate cyclization
C-terminal Lys clipping
Glycation
Glycosylation Characterization
Detailed analysis of glycan profiles and glycosylation patterns.
Analytical Scope:
N-linked glycosylation site identification
N/O glycan profiling
O-linked glycosylation site identification
Glycan distribution analysis
Analytical Support Throughout Product Lifecycle
Analytical requirements evolve throughout biologics development. Protheragen provides tailored analytical support for antibodies, AOCs, and complex biologics, helping clients characterize product quality attributes, monitor development progress, and generate reliable CMC data throughout the product lifecycle.
Discovery & Early Development
Support early molecule evaluation through:
Molecular identity and structural characterization
Purity and heterogeneity analysis
Preliminary biological activity assessment
Process Development
Enable process optimization and quality evaluation through:
Product quality attribute monitoring
Purity and impurity profiling
Process comparability assessment
Formulation & Stability Studies
Evaluate product stability and degradation risks through:
Aggregation and fragmentation analysis
Charge variant monitoring
PTM and degradation characterization
Clinical Development & Regulatory Support
Provide analytical data packages supporting:
Method development and optimization
CQA evaluation
IND/BLA CMC documentation
Advanced Analytical Technologies
Comprehensive analytical characterization requires the integration of multiple complementary analytical technologies to fully understand the molecular properties, quality attributes, and functional performance of antibody therapeutics and antibody-based conjugates. Protheragen utilizes a broad range of advanced analytical platforms to support molecular characterization, process development, quality evaluation, and regulatory documentation. By applying orthogonal analytical approaches, our analytical scientists can identify structural variations, assess product consistency, and generate critical data to support CMC development and regulatory submissions.
Analytical Technology
Primary Application
Critical Quality Attributes
LC-MS/MS
Molecular characterization and structural analysis
Identity, PTMs, sequence, glycosylation
SEC-HPLC
Aggregation and fragment analysis
Purity, molecular integrity
CE-SDS
Size-based purity analysis
Purity, chain integrity
icIEF
Charge heterogeneity analysis
Charge variants, pI
CEX-HPLC
Charge variant profiling
Acidic/basic variants
Glycan Analysis
Glycosylation profiling
Glycan distribution
ELISA / Cell-based Assays
Functional evaluation
Binding activity, potency
HCP / DNA Assays
Residual impurity detection
Process-related impurities
Technology Platform
Protheragen utilizes integrated formulation development and analytical platforms to support the optimization of biologics formulations, evaluation of product stability, and establishment of scalable drug product processes. These capabilities enable the development of stable and manufacturable antibody-based therapeutics from early formulation screening to clinical-stage process optimization.
Formulation Screening & Optimization
Systematic evaluation of formulation conditions, including buffer systems, excipient selection, pH optimization, and protein concentration assessment, to identify optimal formulations for biologics stability.
Biophysical Characterization
Comprehensive characterization of protein properties to evaluate stability, aggregation risks, molecular integrity, and critical quality attributes during formulation development.
Stability Evaluation
Assessment of formulation performance under various storage and stress conditions, including long-term stability, accelerated stability, freeze-thaw stability, and stress studies.
Drug Product Process Development
Optimization of manufacturing-related processes, including mixing, filtration, filling, scale-up, and technology transfer to support clinical and commercial manufacturing readiness.
Why Choose Protheragen
Comprehensive Analytical Capabilities
We provide integrated analytical solutions covering molecular characterization, purity analysis, structural evaluation, biological activity assessment, and critical quality attribute (CQA) analysis for antibodies and complex biologics.
Advanced Analytical Platforms
Our advanced analytical technologies, including LC-MS/MS, SEC-HPLC, CE-SDS, icIEF, CEX-HPLC, and bioassays, enable in-depth characterization and reliable quality evaluation.
Customized CMC Support
We develop fit-for-purpose analytical strategies to support different development stages, including process optimization, formulation studies, stability evaluation, and regulatory submissions.
Regulatory-Oriented Approach
Our analytical methods are designed to generate robust and reliable data packages supporting IND/BLA CMC requirements and global regulatory expectations.
Featured Case Studies
Representative case studies demonstrate our ability to develop reliable analytical solutions for complex biologics characterization and quality evaluation.
CEX Method Optimization for Improved Charge Variant Analysis
Optimization of a charge heterogeneity analysis method by transitioning from salt-gradient CEX to pH-gradient CEX, resulting in improved peak separation and enhanced method robustness.
LC-MS-Based Identification of Polysorbate Degradation Pathways
Development of a comprehensive LC-MS analytical strategy to identify polysorbate oxidation products and investigate degradation mechanisms during long-term stability studies.
Comprehensive analytical characterization is essential for understanding biologic molecules, controlling product quality, and supporting successful CMC development. With advanced analytical platforms and integrated scientific expertise, Protheragen provides reliable analytical method development solutions for antibodies, AOCs, and complex biologics. From early molecular characterization to regulatory submission support, we help clients establish robust analytical strategies that enable informed development decisions and accelerate biologics advancement. Contact us to discuss your analytical development requirements and explore how our integrated analytical capabilities can support your biologics development programs.
Reference
Aithal, R, et al. "Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union" BioDrugs. 2026; 40:713-732.
Fig.1 Key critical quality attributes (CQAs) for monoclonal antibody characterization. (Aithal, R, et al., 2026)
Formulation Screening & Optimization